Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform
- Thursday, December 2, 2021, 2:24
- Business
- Add a comment
UPPSALA, Sweden, Dec. 2, 2021 /PRNewswire/ — Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions. Adrenaline is commonly used for the…
About the Author
adminasapcorp has written 41279 stories on this site.